FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011849510> ?p ?o ?g. }

• W2011849510 endingPage "2250" @default.
• W2011849510 startingPage "2241" @default.
• W2011849510 abstract "CIGB-247 is a novel cancer therapeutic vaccine that uses a human VEGF variant molecule as antigen, in combination with a bacterial adjuvant. In mice, CIGB-247 has anti-tumor and anti-metastatic effects. The vaccine induces anti-VEGF blocking antibodies and a cellular response targeting tumor cells producing VEGF, and has proven to be safe in mice, rats, rabbits and non-human primates. Herein we report the results of a Phase I clinical trial (code name CENTAURO) where safety, tolerance, and immunogenicity of CIGB-247 were studied in 30 patients with advanced solid tumors, at three antigen dose levels. Individuals were subcutaneously immunized for 8 consecutive weeks with 50, 100 or 400 μg of antigen, and re-immunized on week twelve. On week sixteen, evaluations of safety, tolerance, clinical status, and immunogenicity (seroconversion for anti-VEGF IgG, serum VEGF/KDR-Fc blocking ability, and gamma-IFN ELISPOT with blood cells stimulated in vitro with mutated VEGF) were done. Surviving patients were eligible for off-trial additional 4-week re-immunizations with 400 μg of antigen. Immunogenicity and clinical status were again studied on weeks 25 and 49. Vaccination was shown to be safe at the three dose levels, with only grade 1-2 adverse events. CIGB-247 was immunogenic and higher numbers of individuals positive to the three immune response tests were seen with increasing antigen dose. Off-protocol long-term vaccination produced no additional adverse events or negative changes in immunogenicity. Eleven patients are still alive, with overall survivals ranging from 20 to 24 months. Twelve of the thirty patients exhibited objective clinical benefits, and two individuals have complete responses. Most patients with higher survivals are positive in the three immune response tests. In summary, this is the first clinical testing report of a cancer therapeutic vaccine based on a human VEGF related molecule as antigen. The CIGB-247 vaccine is safe, immunogenic, and merits further clinical development.RPCEC00000102. Cuban Public Clinical Trial Registry (WHO accepted Primary Registry). Available from: http://registroclinico.sld.cu/." @default.
• W2011849510 created "2016-06-24" @default.
• W2011849510 creator A5008998982 @default.
• W2011849510 creator A5013593291 @default.
• W2011849510 creator A5033945403 @default.
• W2011849510 creator A5036331237 @default.
• W2011849510 creator A5037222617 @default.
• W2011849510 creator A5047794553 @default.
• W2011849510 creator A5054824174 @default.
• W2011849510 creator A5064618284 @default.
• W2011849510 creator A5073816185 @default.
• W2011849510 creator A5075408516 @default.
• W2011849510 creator A5078213188 @default.
• W2011849510 creator A5081238041 @default.
• W2011849510 creator A5089842487 @default.
• W2011849510 date "2014-04-01" @default.
• W2011849510 modified "2023-09-27" @default.
• W2011849510 title "Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial" @default.
• W2011849510 cites W1491453890 @default.
• W2011849510 cites W192653885 @default.
• W2011849510 cites W1934310225 @default.
• W2011849510 cites W1964348208 @default.
• W2011849510 cites W1965585377 @default.
• W2011849510 cites W1966810480 @default.
• W2011849510 cites W1975058097 @default.
• W2011849510 cites W1976558864 @default.
• W2011849510 cites W1984515783 @default.
• W2011849510 cites W1988283013 @default.
• W2011849510 cites W1989401206 @default.
• W2011849510 cites W1991546842 @default.
• W2011849510 cites W1992878563 @default.
• W2011849510 cites W1998591071 @default.
• W2011849510 cites W2003870597 @default.
• W2011849510 cites W2006024496 @default.
• W2011849510 cites W2006600283 @default.
• W2011849510 cites W2007593267 @default.
• W2011849510 cites W2019607817 @default.
• W2011849510 cites W2022990363 @default.
• W2011849510 cites W2030908446 @default.
• W2011849510 cites W2038158718 @default.
• W2011849510 cites W2038327247 @default.
• W2011849510 cites W2049997077 @default.
• W2011849510 cites W2052877553 @default.
• W2011849510 cites W2054034979 @default.
• W2011849510 cites W2060370107 @default.
• W2011849510 cites W2062036842 @default.
• W2011849510 cites W2064876410 @default.
• W2011849510 cites W2067930723 @default.
• W2011849510 cites W2074516592 @default.
• W2011849510 cites W2075518377 @default.
• W2011849510 cites W2075809315 @default.
• W2011849510 cites W2085069010 @default.
• W2011849510 cites W2087095969 @default.
• W2011849510 cites W2087906374 @default.
• W2011849510 cites W2096825083 @default.
• W2011849510 cites W2097947269 @default.
• W2011849510 cites W2104599421 @default.
• W2011849510 cites W2105871790 @default.
• W2011849510 cites W2116075163 @default.
• W2011849510 cites W2134121541 @default.
• W2011849510 cites W2136267518 @default.
• W2011849510 cites W2139536181 @default.
• W2011849510 cites W2139671659 @default.
• W2011849510 cites W2148609547 @default.
• W2011849510 cites W2149294990 @default.
• W2011849510 cites W2150663100 @default.
• W2011849510 cites W2155020307 @default.
• W2011849510 cites W2156947598 @default.
• W2011849510 cites W2157769714 @default.
• W2011849510 cites W2159443496 @default.
• W2011849510 cites W2793323124 @default.
• W2011849510 doi "https://doi.org/10.1016/j.vaccine.2013.11.102" @default.
• W2011849510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24530151" @default.
• W2011849510 hasPublicationYear "2014" @default.
• W2011849510 type Work @default.
• W2011849510 sameAs 2011849510 @default.
• W2011849510 citedByCount "41" @default.
• W2011849510 countsByYear W20118495102014 @default.
• W2011849510 countsByYear W20118495102015 @default.
• W2011849510 countsByYear W20118495102016 @default.
• W2011849510 countsByYear W20118495102017 @default.
• W2011849510 countsByYear W20118495102018 @default.
• W2011849510 countsByYear W20118495102019 @default.
• W2011849510 countsByYear W20118495102020 @default.
• W2011849510 countsByYear W20118495102021 @default.
• W2011849510 countsByYear W20118495102022 @default.
• W2011849510 countsByYear W20118495102023 @default.
• W2011849510 crossrefType "journal-article" @default.
• W2011849510 hasAuthorship W2011849510A5008998982 @default.
• W2011849510 hasAuthorship W2011849510A5013593291 @default.
• W2011849510 hasAuthorship W2011849510A5033945403 @default.
• W2011849510 hasAuthorship W2011849510A5036331237 @default.
• W2011849510 hasAuthorship W2011849510A5037222617 @default.
• W2011849510 hasAuthorship W2011849510A5047794553 @default.
• W2011849510 hasAuthorship W2011849510A5054824174 @default.
• W2011849510 hasAuthorship W2011849510A5064618284 @default.
• W2011849510 hasAuthorship W2011849510A5073816185 @default.
• W2011849510 hasAuthorship W2011849510A5075408516 @default.

• next